NCT01522664View on ClinicalTrials.gov

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Malignant Melanoma
Interventions
DRUG

DEDN6526A

Multiple ascending doses

Trial Locations (6)

2050

Camperdown

3002

East Melbourne

34232

Sarasota

37203

Nashville

48201

Detroit

90025

Los Angeles

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY